Bradley Canino
Stock Analyst at Stifel
(1.58)
# 3,379
Out of 5,182 analysts
83
Total ratings
32.43%
Success rate
-4.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PYXS Pyxis Oncology | Maintains: Buy | $9 → $8 | $1.45 | +451.72% | 2 | Mar 24, 2026 | |
| JANX Janux Therapeutics | Maintains: Buy | $46 → $38 | $14.94 | +154.35% | 4 | Dec 2, 2025 | |
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $24.29 | +81.14% | 7 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $2.50 | +500.00% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $1.96 | -23.47% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $14.92 | +27.35% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $12.45 | +84.74% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $11.22 | +354.55% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $8.49 | +123.79% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $114.22 | -63.23% | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $40 | $18.69 | +114.02% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $103.71 | +30.17% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $8.91 | +124.47% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $2.69 | +271.75% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.84 | +392.96% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $85.27 | -35.50% | 4 | Feb 23, 2024 |
Pyxis Oncology
Mar 24, 2026
Maintains: Buy
Price Target: $9 → $8
Current: $1.45
Upside: +451.72%
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $46 → $38
Current: $14.94
Upside: +154.35%
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $24.29
Upside: +81.14%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $2.50
Upside: +500.00%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $1.96
Upside: -23.47%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $14.92
Upside: +27.35%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $12.45
Upside: +84.74%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $11.22
Upside: +354.55%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $8.49
Upside: +123.79%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $114.22
Upside: -63.23%
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $18.69
Upside: +114.02%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $103.71
Upside: +30.17%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $8.91
Upside: +124.47%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $2.69
Upside: +271.75%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.84
Upside: +392.96%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $85.27
Upside: -35.50%